Development and Optimization of Novel Tablet Formulations for Enhanced Bioavailability and Therapeutic Efficacy

Abstract

The present study focuses on the design, development, and optimization of novel tablet formulations aimed at enhancing both bioavailability and therapeutic efficacy of a selected active pharmaceutical ingredient (API) with limited solubility and absorption characteristics. Oral drug delivery remains the most preferred route of administration; however, conventional tablet dosage forms often suffer from suboptimal dissolution profiles and incomplete absorption, ultimately reducing clinical effectiveness. This research addresses these limitations through the application of innovative formulation strategies, including the use of optimized excipient blends, advanced disintegration enhancers, and process parameter control [1,2].

A total of 1000 samples were prepared across multiple formulation batches using a systematic Design of Experiments (DOE) approach to identify critical factors influencing drug release and absorption [3,4]. Each batch underwent comprehensive physicochemical evaluation—including hardness, friability, weight variation, disintegration time, and in vitro dissolution testing—followed by bioavailability assessment using in vitro–in vivo correlation (IVIVC) models [5,6]. The influence of formulation variables such as particle size distribution, binder concentration, superdisintegrant type, and compression force was statistically analyzed using analysis of variance (ANOVA) and response surface methodology (RSM) to establish an optimal formulation profile [7,8].

The optimized formulation demonstrated a significant improvement in dissolution rate, achieving over 85% drug release within the first 30 minutes compared to the conventional control, and exhibited a marked increase in predicted bioavailability. Enhanced therapeutic efficacy was validated through simulated pharmacokinetic modeling, showing improved maximum plasma concentration (Cmax) and reduced time to reach peak concentration (Tmax) [9,10].

This research not only provides a detailed account of the formulation development process but also outlines a scientifically validated optimization pathway for translating laboratory-scale improvements into industrial-scale production. The findings offer substantial potential for commercialization and clinical application, contributing to the advancement of more effective oral dosage forms that address the persistent challenge of poor bioavailability in pharmaceutical drug delivery systems [11].